- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07581470
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function.
Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia.
Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established.
This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Małgorzata Reysner, MD PhD
- Puhelinnumero: +48 (61) 8310122
- Sähköposti: mreysner@ump.edu.pl
Tutki yhteystietojen varmuuskopiointi
- Nimi: Tomasz Reysner, MD PhD
- Puhelinnumero: +48 (61) 8310122
- Sähköposti: mreysner@ump.edu.pl
Opiskelupaikat
-
-
-
Poznan, Puola, 62-701
- Rekrytointi
- Poznan University of Medical Sciences
-
Ottaa yhteyttä:
- Malgorzata Reysner, M.D. Ph.D.
- Puhelinnumero: +48 61 873 83 03
- Sähköposti: mreysner@ump.edu.pl
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥ 18 years
- Scheduled for elective total hip arthroplasty (THA)
- Planned use of regional anesthesia including PENG block
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to understand the study procedures and provide written informed consent
- Ability to assess pain using the Numeric Rating Scale (NRS)
Exclusion Criteria:
- Known hypersensitivity to dexamethasone or any component of the study medication
- Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery
- Active systemic infection or sepsis
- Significant immunosuppression (e.g., chemotherapy, biological therapy)
- Pregnancy or breastfeeding
- Severe cognitive impairment or inability to reliably assess pain
- Uncontrolled diabetes mellitus (e.g., HbA1c > 8.5% or baseline blood glucose > 200 mg/dL)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Placebo Comparator: Placebo (0 mg Intravenous Dexamethasone)
Participants receive placebo (0.9% sodium chloride) administered intravenously in a volume identical to active treatment after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.
Muut nimet:
|
|
Active Comparator: Dexamethasone 4 mg Intravenous
Participants receive 4 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg
Muut nimet:
|
|
Active Comparator: Dexamethasone 8 mg Intravenous
Participants receive 8 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to First Rescue Analgesia
Aikaikkuna: 48 hours after surgery
|
Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request). |
48 hours after surgery
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Postoperative Pain Intensity
Aikaikkuna: 6 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
6 hours after surgery
|
|
Postoperative Pain Intensity
Aikaikkuna: 12 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
12 hours after surgery
|
|
Postoperative Pain Intensity
Aikaikkuna: 24 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
24 hours after surgery
|
|
Postoperative Pain Intensity
Aikaikkuna: 48 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
48 hours after surgery
|
|
Opioid Consumption
Aikaikkuna: 48 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
48 hours after surgery
|
|
Opioid Consumption
Aikaikkuna: 24 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
24 hours after surgery
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
Aikaikkuna: 24 hours after surgery
|
Occurrence of nausea and/or vomiting and need for antiemetic treatment. |
24 hours after surgery
|
|
Blood Glucose Levels
Aikaikkuna: immidietly after surgery (0 hours after surgery)
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
immidietly after surgery (0 hours after surgery)
|
|
Blood Glucose Levels
Aikaikkuna: 6 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
6 hours after surgery
|
|
Blood Glucose Levels
Aikaikkuna: 12 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
12 hours after surgery
|
|
Blood Glucose Levels
Aikaikkuna: 24 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
24 hours after surgery
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Justyna Marszałek-Buko, MD, Poznan University of Medical Sciences
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Tuki- ja liikuntaelinten sairaudet
- Niveltulehdus
- Nivelsairaudet
- Reumaattiset sairaudet
- Nivelrikko
- Nivelrikko, lonkka
- Polisykliset yhdisteet
- Epäorgaaniset kemikaalit
- Klooriyhdisteet
- Raskaat
- Raskaat
- Steroidit
- Sulatettu rengasyhdisteet
- Fluoratut steroidit
- Raskaat
- Natriumyhdisteet
- Kloridit
- Suolahappo
- Deksametasoni
- Deksametasonia 21-fosfaatti
- Natriumkloridi
Muut tutkimustunnusnumerot
- 3/2026
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .